Dr Eric Kusnadi
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
29 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Abstract SY24-02: Di-codon organization links tRNA modifications to cancer cell proteome composition
DOI: 10.1158/1538-7445.am2026-sy24-022026
Journal article
Abstract 427: PMR-116, a second-generation RNA polymerase I inhibitor displaying therapeutic efficacy in a broad spectrum of malignancies.
DOI: 10.1158/1538-7445.am2026-4272026
Journal article
Abstract 601: Translational reprogramming disrupts mitosis to drive SMAD4-deficient esophageal adenocarcinoma.
DOI: 10.1158/1538-7445.am2026-6012025
Journal article
77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial
DOI: 10.1016/j.esmoop.2025.1054272024
Journal article
Second generation RNA Polymerase I inhibitor PMR-116 targets ribsomal RNA synthesis to potently treat a broad spectrum of malignancies
DOI: 10.1158/1538-8514.RNADRIVERS24-PR0042024
Conference Proceedings
Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions
DOI: 10.1158/1538-8514.SYNTHLETH24-PR0072024
Conference Proceedings
Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions
DOI: 10.1158/1538-8514.SYNTHLETH24-A006
RECENT SCHOLARLY WORKS
2024
Conference Proceedings
PMR-116, a second generation RNA Polymerase I inhibitor
DOI: 10.1158/1538-7445.AM2024-33262024
Journal article
Multi-omics approach reveals a SMAD4-deficiency signature, translational reprogramming and synthetic lethality in esophageal adenocarcinom
DOI: 10.1158/1538-7445.AM2024-55782023
Conference Proceedings
Loss of SMAD4 unleashes mTOR and increases dependency on cap-dependent translation in esophageal tumorigenesis
DOI: 10.1158/1535-7163.TARG-23-A176